MDXHEALTH Stock Nasdaq
Equities
MDXH
US58286E1029
Biotechnology & Medical Research
Sales 2024 * | 78.66M 85.35M | Sales 2025 * | 89.78M 97.41M | Capitalization | 68.49M 74.31M |
---|---|---|---|---|---|
Net income 2024 * | -26M -28.21M | Net income 2025 * | -17M -18.44M | EV / Sales 2024 * | 2.18 x |
Net Debt 2024 * | 103M 112M | Net Debt 2025 * | 121M 131M | EV / Sales 2025 * | 2.11 x |
P/E ratio 2024 * |
-2.75
x | P/E ratio 2025 * |
-4.07
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.92% |
Latest transcript on MDXHEALTH
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 19-02-17 | |
Ron Kalfus
DFI | Director of Finance/CFO | 50 | 19-07-21 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Donnie Hardison
BRD | Director/Board Member | 74 | 21-09-28 |
Eric Bednarski
BRD | Director/Board Member | 52 | 20-07-29 |
Hilde Windels
BRD | Director/Board Member | 59 | 17-10-31 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |